Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study
British Journal of Clinical Pharmacology · 2026-06 · 92 (6) · 1595-1606
DOI: 10.1002/bcp.70415 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 15.12.2025. Verfasst von Andriy A Gorbenko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Amitriptyline, Cannabidiol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.
Abstract (Originalsprache)
Aims
Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol, two commonly used analgesics.
Methods
This was an open‐label, fixed‐sequence, 2‐way crossover study in 13 healthy participants. On Day 1, 25 mg amitriptyline and 50 mg tramadol were co‐administered orally in a fasted condition, followed by a 7‐day washout period. On Day 8, 30 mg CBD was administered orally 1 h prior to amitriptyline and tramadol. Pharmacokinetic sampling was performed for CBD, amitriptyline, tramadol and their respective active metabolites nortriptyline and O‐desmethyltramadol for up to 24 h post‐dose. The areas under the curve (AUCs) were compared between visits using a mixed effects model.
Results
Twelve participants (4M/8F) completed the study; one participant (M) dropped out for personal reasons. CBD significantly increased the AUC 0‐24h (least square means [LSM] ratio 1.13, 95% CI: 1.01, 1.26, p = 0.033) and the C max (LSM ratio 1.17, 95% CI: 1.01, 1.36, p = 0.041 ) of amitriptyline. CBD did not significantly change the AUC 0‐24h and C max of nortriptyline and tramadol, and the C max of O‐desmethyltramadol.
Conclusions
A single dose of 30 mg CBD significantly influenced the metabolism of amitriptyline in healthy volunteers. In patients, CBD‐induced drug interactions may be more pronounced in chronic dosing and dependent upon prandial status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Human Drug Research, Leiden, The Netherlands.
- Leiden University Medical Centre, Leiden, The Netherlands.
- Verdient Science, LLC., Denver, CO, USA.
- Tomori Pharmacology, Inc., Denver, CO, USA.
- Larner College of Medicine, University of Vermont, Burlington, VT, USA.
- Centre for Future Affordable and Sustainable Therapy development (FAST), the Hague, the Netherlands.
ORCID-Profile: Andriy A Gorbenko, Titiaan E Post, Pamela K Strugala, Erica S Klaassen, Linda E Klumpers, Saco J de Visser, Cristina Sempio, Jost Klawitter, Jules A A C Heuberger, Geert J Groeneveld
Förderung
- ZonMw
Zitieren
APA
Gorbenko, A. A., Post, T. E., Strugala, P. K., Klaassen, E. S., Klumpers, L. E., de Visser, S. J., Sempio, C., Klawitter, J., Heuberger, J. A. A. C., & Groeneveld, G. J. (2026). Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology, 92(6), 1595-1606. https://doi.org/10.1002/bcp.70415
Vancouver
Gorbenko AA, Post TE, Strugala PK, Klaassen ES, Klumpers LE, de Visser SJ, et al. Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study. British Journal of Clinical Pharmacology. 2026;92(6):1595-1606. doi:10.1002/bcp.70415
BibTeX
@article{Gorbenko2026,
author = {Gorbenko, Andriy A and Post, Titiaan E and Strugala, Pamela K and Klaassen, Erica S and Klumpers, Linda E and de Visser, Saco J and Sempio, Cristina and Klawitter, Jost and Heuberger, Jules A A C and Groeneveld, Geert J},
title = {Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {6},
pages = {1595--1606},
doi = {10.1002/bcp.70415}
}
EUVIMED